MedAvante is a global provider of centralized, expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of failed studies. MedAvante applies its unique methodology to systematically remove potential sources of bias and variability from the diagnosis and assessment process. By centralizing assessments with expert raters utilizing real-time, remote conferencing, MedAvante makes subjective assessments of subject selection and drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates, enabling them to bring more effective CNS drugs to market sooner.

The MedAvante methodology was developed by members of our scientific leadership team, including thought leaders in psychiatric assessment and clinical trials from academia and leading global pharmaceutical companies. Each MedAvante senior scientist has engaged in funded research examining improved assessment methodologies, has authored psychiatric scales, or has led efforts to update current scales. Our senior scientists provide oversight of our expert raters and ensure research quality for study sponsors.
 
Confidence in the MedAvante methodology and its ability to decrease the number of failed CNS clinical studies has been demonstrated by an impressive cast of investors and a growing number of sponsors. Investments include $20 million from Goldman Sachs and Trevi Health and a prior $14 million from organizational leaders representing retired pharmaceutical executives, Wall Street, and innovative growth company CEOs, who continue to provide MedAvante with expertise and insight.